Serine/Threonine-Protein Kinase Chk2 clinical trials
19 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones look like a fit.
- High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
- Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
- Responses to Genetic Risk Modifier Testing Among Women With Pathogenic Variants in Breast Cancer Predisposition Genes
- Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer
- Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
- Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- Prostate Cancer Genetic Risk Evaluation and Screening Study
- Men at High Genetic Risk for Prostate Cancer
- Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
- [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
- Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
- High-Risk Metachronous Oligometastatic Prostate Cancer Trial
- Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
- Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “Serine/Threonine-Protein Kinase Chk2” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.